Feasibility of a randomized controlled trial of vitamin D vs. placebo in women with recently diagnosed breast cancer

被引:12
作者
Cescon, David W. [1 ,2 ]
Ganz, Patricia A. [3 ,4 ]
Beddows, Samantha [1 ]
Ennis, Marguerite
Mills, Barbara K. [4 ]
Goodwin, Pamela J. [1 ,2 ]
机构
[1] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
[2] Univ Toronto, Div Med Oncol & Hematol, Toronto, ON, Canada
[3] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA
[4] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA
关键词
Breast cancer; Vitamin D; Adjuvant therapy; Randomized controlled trials; Outcomes; 25-HYDROXYVITAMIN D; PROSTATE-CANCER; MUTANT P53; RISK; SUPPLEMENTATION;
D O I
10.1007/s10549-012-2120-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Low serum vitamin D levels have been associated with poor outcomes in women diagnosed with early breast cancer. However, no randomized controlled trials (RCTs) have been performed to determine whether vitamin D supplementation might be an effective intervention in this population. We prospectively evaluated vitamin D adequacy and supplementation rates in a contemporary cross-sectional sample of breast cancer patients from 2 large urban centers and examined the feasibility of an RCT of vitamin D supplementation. Women with recently diagnosed early breast cancer were prospectively identified and recruited in Toronto and Los Angeles between March 2009 and January 2010. Anthropometric measurements, dietary, lifestyle, and medication histories were obtained by means of structured questionnaires and interviews. Tumor and treatment characteristics were abstracted from clinical records and blood samples were collected for analysis of 25-OH vitamin D. 173 eligible patients (median age 57) were enrolled. Clinical and treatment characteristics were similar between centres. 84.4 % of women reported use of vitamin D-containing supplements with median daily doses of 1,400 IU. Median 25-OH vitamin D levels were 85.5 and 98.5 nmol/L (P = 0.1), and levels of deficiency (< 50 nmol/L), insufficiency (50-72 nmol/L), and adequacy (> 72 nmol/L) were 3.8, 23.8, 72.5 % (Toronto) and 4.3, 20.7, 75 % (Los Angeles). 25-OH vitamin D levels were strongly correlated with vitamin D supplement use (r = 0.41, P < 0.0001). 68 % of women expressed willingness to participate in a vitamin D supplementation RCT; however, only 12.7 % of the study population met the pre-specified feasibility criteria (25-OH vitamin D < 72 nmol/L, willing to participate, and taking a parts per thousand currency sign1,000 IU vitamin D supplement/day). Both vitamin D levels and supplementation rates are higher than in previous reports. While the majority of women would be willing to participate in an RCT of vitamin D supplementation, low levels of deficiency/insufficiency and high rates of supplement use would limit the feasibility of such a study.
引用
收藏
页码:759 / 767
页数:9
相关论文
共 24 条
[1]   Serum vitamin D concentration and prostate cancer risk: A nested case-control study [J].
Ahn, Jiyoung ;
Peters, Ulrike ;
Albanes, Demetrius ;
Purdue, Mark P. ;
Abnet, Christian C. ;
Chatterjee, Nilanjan ;
Horst, Ronald L. ;
Hollis, Bruce W. ;
Huang, Wen-Yi ;
Shikany, James M. ;
Hayes, Richard B. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (11) :796-804
[2]   Vitamin D and calcium intakes and breast cancer risk in pre- and postmenopausal women [J].
Anderson, Laura N. ;
Cotterchio, Michelle ;
Vieth, Reinhold ;
Knight, Julia A. .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2010, 91 (06) :1699-1707
[3]  
[Anonymous], 2010, Canadian Health Measures Survey (CHMS) data user guide: cycle 1
[4]  
[Anonymous], 2011, DIETARY REFERENCE IN
[5]   A DATA-BASED APPROACH TO DIET QUESTIONNAIRE DESIGN AND TESTING [J].
BLOCK, G ;
HARTMAN, AM ;
DRESSER, CM ;
CARROLL, MD ;
GANNON, J ;
GARDNER, L .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1986, 124 (03) :453-469
[6]   Vitamin D and breast cancer: interpreting current evidence [J].
Chlebowski, Rowan T. .
BREAST CANCER RESEARCH, 2011, 13 (04)
[7]   Calcium Plus Vitamin D Supplementation and the Risk of Breast Cancer [J].
Chlebowski, Rowan T. ;
Johnson, Karen C. ;
Kooperberg, Charles ;
Pettinger, Mary ;
Wactawski-Wende, Jean ;
Rohan, Tom ;
Rossouw, Jacques ;
Lane, Dorothy ;
O'Sullivan, Mary Jo ;
Yasmeen, Shagufta ;
Hiatt, Robert A. ;
Shikany, James M. ;
Vitolins, Mara ;
Khandekar, Janu ;
Hubbell, F. Allan .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (22) :1581-1591
[8]   Prognostic Effects of 25-Hydroxyvitamin D Levels in Early Breast Cancer [J].
Goodwin, Pamela J. ;
Ennis, Marguerite ;
Pritchard, Kathleen I. ;
Koo, Jarley ;
Hood, Nicky .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) :3757-3763
[9]   Vitamin D in Cancer Patients: Above All, Do No Harm [J].
Goodwin, Pamela J. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (13) :2117-2119
[10]   Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment [J].
Hadji, P. ;
Aapro, M. S. ;
Body, J. J. ;
Bundred, N. J. ;
Brufsky, A. ;
Coleman, R. E. ;
Gnant, M. ;
Guise, T. ;
Lipton, A. .
ANNALS OF ONCOLOGY, 2011, 22 (12) :2546-2555